Of the three classes of medicine identified in the Canadian switch report, one is already available OTC in the U.S. and a second is expected to be under consideration for non-prescription status this year.
H.R. 749 is intended to require the U.S. Food and Drug Administration to act upon applications for generic drugs within 180 days of being filed that are in short supply or when there are too few manufacturers on the market is being revised.
New plans would no longer penalize Americans for failing to have health insurance, instead opting to encourage Americans to keep medical coverage by allowing insurance to pose a surcharge of 30% for those who have a gap between plans.
Specialty and biotech medicines aimed at treating cancer, multiple sclerosis and rare diseases will dominate much of drug development in 2017 and beyond, one of the nation’s top specialty pharmacy providers concluded.